Affordability of risperidone and aripiprazole for the treatment of autism spectrum disorder

Please use this identifier to cite or link to this item: https://www.um.edu.mt/library/oar/handle/123456789/48851

Title:	Affordability of risperidone and aripiprazole for the treatment of autism spectrum disorder
Authors:	Sadaf, Shaista Mifsud Buhagiar, Luana Zarb Adami, Maurice Attard Pizzuto, Maresca Serracino-Inglott, Anthony
Keywords:	Autism spectrum disorders -- Treatment Autism spectrum disorders -- Malta -- Case studies Autism spectrum disorders -- India -- Case studies Autism spectrum disorders -- Comparative studies Risperidone Aripiprazole
Issue Date:	2018-09
Publisher:	University of Malta. Department of Pharmacy
Citation:	Sadaf, S., Mifsud Buhagiar, L., Zarb Adami, M., Attard Pizzuto, M., & Serracino-Inglott, A. (2018, September). Affordability of risperidone and aripiprazole for the treatment of autism spectrum disorder. Poster session presented at the 78th FIP World Congress of Pharmacy and Pharmaceutical Sciences, Glasgow, United Kingdom.
Abstract:	A poster presentation regarding the affordability of risperidone and aripiprazole for the treatment of autism spectrum disorder. Introduction: The use of risperidone and aripiprazole in children and adolescents with Autism Spectrum Disorder (ASD) is off-label in India and Malta and is not included in the national formularies. The European Medicines Agency and the Central Drug Standard Control Organisation (India) have not approved the drug for the indication of ASD. Aims: To compare the use and cost of the treatment of irritability associated with autism using risperidone and aripiprazole, in India and Malta.
URI:	https://www.um.edu.mt/library/oar/handle/123456789/48851
Appears in Collections:	Scholarly Works - FacM&SPha

Files in This Item:

File	Description	Size	Format
Affordability_of_risperidone_and_aripiprazole_for_the_treatment_of_autism_spectrum_disorder_2018.pdf		568.58 kB	Adobe PDF	View/Open

Show full item record Statistics